Englander Institute for Precision Medicine

Prostate cancer hijacks the normal prostate’s growth regulation program to release the brakes and grow freely, according to Weill Cornell Medicine researchers.

Three teams led by Weill Cornell Medicine scientists have received awards from the Starr Cancer Consortium in its 17th and final annual grant competition

A new artificial intelligence-based system can accurately assess the chromosomal status of in vitro-fertilized (IVF) embryos using only time-lapse video images of the embryos and maternal age, according to a study from investigators at Weill Cornell Medicine.

How bladder cancer originates and progresses has been illuminated as never before in a study led by researchers at Weill Cornell Medicine and the New York Genome Center. 

A common mutation in the KRAS gene is associated with improved overall survival in pancreatic ductal adenocarcinoma (PDAC) compared with other variants, in part because the mutation appears to lead to less invasiveness and weaker biological activity, according to a multicenter study conducted at Weill Cornell Medicine, Memorial Sloan Kettering, and other institutions.

Stimulating a key metabolic pathway in T cells can make them work more effectively against tumors when combined with immune checkpoint inhibitor therapy, according to a preclinical study led by researchers at Weill Cornell Medicine.

A powerful new analytical tool offers a closer look at how tumor cells “shape-shift” to become more aggressive and untreatable, as shown in a study from researchers at Weill Cornell Medicine and the New York Genome Center.

Scientists at Weill Cornell Medicine in Qatar (WCM-Q) have created an intricate molecular map of the human body and its complex physiological processes based on the analysis of thousands of molecules measured in blood, urine and saliva samples from 391 volunteers.

Researchers at Weill Cornell Medicine have used artificial intelligence to identify drug targets based on mapping regulatory networks in patient tumors.

A team co-led by researchers at Weill Cornell Medicine and the New York Genome Center has developed an advanced method for revealing how gene mutations disrupt the normal packaging of DNA. 

Weill Cornell Medicine is part of an international team that has been awarded funding of up to $25 million over five years by Cancer Grand Challenges to study the causes of cancer inequities.

Male breast cancer has distinct alterations in the tumor genome that may suggest potential treatment targets, according to a study by Weill Cornell Medicine investigators.

Weill Cornell Medicine researchers received a $2.4 million grant from the U.S. Department of Defense Breast Cancer Research Program to validate a new blood test for the early detection of breast cancer.

A historic investment from Board of Fellows member Israel Englander will advance Weill Cornell Medicine’s growing research enterprise and support critical initiatives throughout the institution. 

Located one block from Weill Cornell Medicine’s main campus on Manhattan’s Upper East Side, the site will add approximately 200,000 square feet of dedicated research space. 

Dr. Bishoy M. Faltas, the Gellert Family-John P. Leonard, M.D. Research Scholar and an assistant professor of medicine at Weill Cornell Medicine, has been awarded a $4 million, seven-year MERIT grant from the National Cancer Institute (NCI) at the National Institutes of Health (NIH).

Researchers at Weill Cornell Medicine have performed the most comprehensive analysis to date of cancer of the ureters or the urine-collection cavities in the kidney, known as upper tract urothelial carcinoma (UTUC). 

The designation adds the academic medical center to NORD’s collaborative network of 40 participating institutions that research and treat rare diseases.

An atlas that catalogues gene activity and the levels of small molecules called metabolites in tumor samples offers a new way of identifying the deep mechanisms of cancer, according to researchers at Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center.

Nearly 90 percent of patients with an aggressive subtype of non-Hodgkin lymphoma had their cancer go into remission in a small phase 2 clinical trial testing a treatment aimed at making chemotherapy more effective, according to Weill Cornell Medicine and NewYork-Presbyterian investigators.